Literature DB >> 17944451

Synthesis and evaluation of 3-aryloxymethyl-1,2-dimethylindole-4,7-diones as mechanism-based inhibitors of NAD(P)H:quinone oxidoreductase 1 (NQO1) activity.

Marie A Colucci1, Philip Reigan, David Siegel, Aurélie Chilloux, David Ross, Christopher J Moody.   

Abstract

NAD(P)H:quinone oxidoreductase 1 is a proposed target in pancreatic cancer. We describe the synthesis of a series of indolequinones, based on the 5- and 6-methoxy-1,2-dimethylindole-4,7-dione chromophores with a range of phenolic leaving groups at the (indol-3-yl)methyl position. The ability of these indolequinones to function as mechanism-based inhibitors of purified recombinant human NQO1 was evaluated, as was their ability to inhibit both NQO1 and cell growth in human pancreatic MIA PaCa-2 tumor cells. The inhibition of rhNQO1 was related to the pKa of the leaving group: compounds with poorer phenolic leaving groups were poor inhibitors whereas those with more acidic leaving groups were more efficient inhibitors. These inhibition data also correlated with the inhibition NQO1 in MIA PaCa-2 cells. However, the data demonstrate that NQO1 inhibition does not correlate with growth inhibitory activity, at least in the MIA PaCa-2 cell line, suggesting that targets in addition to NQO1 need to be considered to explain the potent growth inhibitory activity of this series of indolequinones in human pancreatic cancer cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17944451      PMCID: PMC2536657          DOI: 10.1021/jm070396q

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  20 in total

Review 1.  Enzymology of bioreductive drug activation.

Authors:  D Ross; H D Beall; D Siegel; R D Traver; D L Gustafson
Journal:  Br J Cancer Suppl       Date:  1996-07

2.  5-Methoxy-1,2-dimethyl-3-[(4-nitrophenoxy)methyl]indole-4,7-dione, a mechanism-based inhibitor of NAD(P)H:quinone oxidoreductase 1, exhibits activity against human pancreatic cancer in vitro and in vivo.

Authors:  Donna L Dehn; David Siegel; Khan Shoeb Zafar; Philip Reigan; Elizabeth Swann; Christopher J Moody; David Ross
Journal:  Mol Cancer Ther       Date:  2006-07       Impact factor: 6.261

3.  Indolequinone antitumor agents: correlation between quinone structure, rate of metabolism by recombinant human NAD(P)H:quinone oxidoreductase, and in vitro cytotoxicity.

Authors:  H D Beall; S Winski; E Swann; A R Hudnott; A S Cotterill; N O'Sullivan; S J Green; R Bien; D Siegel; D Ross; C J Moody
Journal:  J Med Chem       Date:  1998-11-19       Impact factor: 7.446

4.  Metabolism of bioreductive antitumor compounds by purified rat and human DT-diaphorases.

Authors:  H D Beall; R T Mulcahy; D Siegel; R D Traver; N W Gibson; D Ross
Journal:  Cancer Res       Date:  1994-06-15       Impact factor: 12.701

5.  NAD(P)H:quinone oxidoreductase 1: role as a superoxide scavenger.

Authors:  David Siegel; Daniel L Gustafson; Donna L Dehn; Jin Yi Han; Preecha Boonchoong; Lawrence J Berliner; David Ross
Journal:  Mol Pharmacol       Date:  2004-05       Impact factor: 4.436

6.  Development of indolequinone mechanism-based inhibitors of NAD(P)H:quinone oxidoreductase 1 (NQO1): NQO1 inhibition and growth inhibitory activity in human pancreatic MIA PaCa-2 cancer cells.

Authors:  Philip Reigan; Marie A Colucci; David Siegel; Aurélie Chilloux; Christopher J Moody; David Ross
Journal:  Biochemistry       Date:  2007-04-25       Impact factor: 3.162

Review 7.  DT-diaphorase in activation and detoxification of quinones. Bioreductive activation of mitomycin C.

Authors:  D Ross; D Siegel; H Beall; A S Prakash; R T Mulcahy; N W Gibson
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

8.  Novel quinolinequinone antitumor agents: structure-metabolism studies with NAD(P)H:quinone oxidoreductase (NQO1).

Authors:  Tara Fryatt; Hanna I Pettersson; Walter T Gardipee; Kurtis C Bray; Stephen J Green; Alexandra M Z Slawin; Howard D Beall; Christopher J Moody
Journal:  Bioorg Med Chem       Date:  2004-04-01       Impact factor: 3.641

9.  Cyclopropamitosenes, novel bioreductive anticancer agents. Synthesis, electrochemistry, and biological activity of 7-substituted cyclopropamitosenes and related indolequinones.

Authors:  A S Cotterill; C J Moody; R J Mortimer; C L Norton; N O'Sullivan; M A Stephens; N R Stradiotto; E Swann; I J Stratford
Journal:  J Med Chem       Date:  1994-10-28       Impact factor: 7.446

10.  Indolequinone antitumor agents: reductive activation and elimination from (5-methoxy-1-methyl-4,7-dioxoindol-3-yl)methyl derivatives and hypoxia-selective cytotoxicity in vitro.

Authors:  M A Naylor; E Swann; S A Everett; M Jaffar; J Nolan; N Robertson; S D Lockyer; K B Patel; M F Dennis; M R Stratford; P Wardman; G E Adams; C J Moody; I J Stratford
Journal:  J Med Chem       Date:  1998-07-16       Impact factor: 7.446

View more
  9 in total

1.  Antitumor indolequinones induced apoptosis in human pancreatic cancer cells via inhibition of thioredoxin reductase and activation of redox signaling.

Authors:  Chao Yan; David Siegel; Jeffery Newsome; Aurelie Chilloux; Christopher J Moody; David Ross
Journal:  Mol Pharmacol       Date:  2011-12-06       Impact factor: 4.436

2.  Indolequinone inhibitors of NRH:quinone oxidoreductase 2. Characterization of the mechanism of inhibition in both cell-free and cellular systems.

Authors:  Chao Yan; Marine Dufour; David Siegel; Philip Reigan; Joe Gomez; Biehuoy Shieh; Christopher J Moody; David Ross
Journal:  Biochemistry       Date:  2011-07-19       Impact factor: 3.162

3.  Mechanism-based inhibition of quinone reductase 2 (NQO2): selectivity for NQO2 over NQO1 and structural basis for flavoprotein inhibition.

Authors:  Marine Dufour; Chao Yan; David Siegel; Marie A Colucci; Matthew Jenner; Neil J Oldham; Joe Gomez; Philip Reigan; Yazhuo Li; Cristina I De Matteis; David Ross; Christopher J Moody
Journal:  Chembiochem       Date:  2011-04-19       Impact factor: 3.164

4.  Potent activity of indolequinones against human pancreatic cancer: identification of thioredoxin reductase as a potential target.

Authors:  Chao Yan; Biehuoy Shieh; Philip Reigan; Zhiyong Zhang; Marie A Colucci; Aurélie Chilloux; Jeffery J Newsome; David Siegel; Dan Chan; Christopher J Moody; David Ross
Journal:  Mol Pharmacol       Date:  2009-04-13       Impact factor: 4.436

5.  Effect of β-Eudesmol on NQO1 suppression-enhanced sensitivity of cholangiocarcinoma cells to chemotherapeutic agents.

Authors:  Pimradasiri Srijiwangsa; Saranyoo Ponnikorn; Kesara Na-Bangchang
Journal:  BMC Pharmacol Toxicol       Date:  2018-06-19       Impact factor: 2.483

Review 6.  NAD(P)H quinone oxidoreductase (NQO1): an enzyme which needs just enough mobility, in just the right places.

Authors:  Angel L Pey; Clare F Megarity; David J Timson
Journal:  Biosci Rep       Date:  2019-01-03       Impact factor: 3.840

7.  Mesoporous Silica Nanoparticle-Based Combination of NQO1 Inhibitor and 5-Fluorouracil for Potent Antitumor Effect Against Head and Neck Squamous Cell Carcinoma (HNSCC).

Authors:  Jing Chen; Shuzhen Zhang; Shuai Zhang; Shanjun Gao; Jianbo Wang; Dongchun Lei; Pengqiang Du; Zhiwei Xu; Cailiang Zhu; Hongbin Sun
Journal:  Nanoscale Res Lett       Date:  2019-12-19       Impact factor: 4.703

8.  Virtual Screening for Potential Phytobioactives as Therapeutic Leads to Inhibit NQO1 for Selective Anticancer Therapy.

Authors:  Bhargav Shreevatsa; Chandan Dharmashekara; Vikas Halasumane Swamy; Meghana V Gowda; Raghu Ram Achar; Vivek Hamse Kameshwar; Rajesh Kumar Thimmulappa; Asad Syed; Abdallah M Elgorban; Salim S Al-Rejaie; Joaquín Ortega-Castro; Juan Frau; Norma Flores-Holguín; Chandan Shivamallu; Shiva Prasad Kollur; Daniel Glossman-Mitnik
Journal:  Molecules       Date:  2021-11-14       Impact factor: 4.411

9.  Copper(II)-Mediated Synthesis of Indolequinones from Bromoquinones and Enamines.

Authors:  Martyn Inman; Christopher J Moody
Journal:  European J Org Chem       Date:  2013-02-20
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.